tretinoin has been researched along with erteberel* in 1 studies
1 other study(ies) available for tretinoin and erteberel
Article | Year |
---|---|
Drivers and suppressors of triple-negative breast cancer.
To identify regulators of triple-negative breast cancer (TNBC), gene expression profiles of malignant parts of TNBC (mTNBC) and normal adjacent (nadj) parts of the same breasts have been compared. We are interested in the roles of estrogen receptor β (ERβ) and the cytochrome P450 family (CYPs) as drivers of TNBC. We examined by RNA sequencing the mTNBC and nadj parts of five women. We found more than a fivefold elevation in mTNBC of genes already known to be expressed in TNBC: BIRC5/survivin, Wnt-10A and -7B, matrix metalloproteinases (MMPs), chemokines, anterior gradient proteins, and lysophosphatidic acid receptor and the known basal characteristics of TNBC, sox10, ROPN1B, and Col9a3. There were two unexpected findings: 1) a strong induction of CYPs involved in activation of fatty acids (CYP4), and in inactivation of calcitriol (CYP24A1) and retinoic acid (CYP26A1); and 2) a marked down-regulation of FOS, FRA1, and JUN, known tethering partners of ERβ. ERβ is expressed in 20 to 30% of TNBCs and is being evaluated as a target for treating TNBC. We used ERβ Topics: Amphibian Proteins; Animals; Benzopyrans; Calcitriol; Cytochrome P-450 Enzyme System; Down-Regulation; Estrogen Receptor alpha; Estrogen Receptor beta; Fatty Acids; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasms, Experimental; Random Allocation; Survivin; Transcriptome; Tretinoin; Triple Negative Breast Neoplasms; Wnt Proteins | 2021 |